Oral Faropenem Sodium — Implications for Antimicrobial Resistance and Treatment Effectiveness
- 1 November 2022
- journal article
- research article
- Published by Springer Nature in Indian Pediatrics
- Vol. 59 (11) , 879-881
Abstract
Rising antimicrobial resistance (AMR) is causing therapeutic failures with antibiotics. Inappropriate use is a contributing factor. One such antibiotic on the radar is faropenem, a broad spectrum antibiotic approved in 2005 in India. Recently, faropenem sodium suspension was approved for use in children. There is a potential danger of overuse due to the convenience of oral administration. Other carbapenems such as meropenem are used parenterally. Overuse of faropenem may promote cross-resistance with other carbapenems making them ineffective.Keywords
This publication has 7 references indexed in Scilit:
- Faropenem resistance causes in vitro cross-resistance to carbapenems in ESBL-producing Escherichia coliInternational Journal of Antimicrobial Agents, 2020
- High Reported Rates of Antimicrobial Resistance in Indian Neonatal and Pediatric Blood Stream InfectionsJournal of the Pediatric Infectious Diseases Society, 2017
- The Need for Global Regulation of Antibiotics: The Case of a Generic Oral PenemClinical Infectious Diseases, 2016
- Faropenem Consumption is Increasing in IndiaClinical Infectious Diseases, 2016
- Faropenem MedoxomilDrugs in R&D, 2008
- National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance StudyAntimicrobial Agents and Chemotherapy, 2007
- Faropenem: review of a new oral penemExpert Review of Anti-infective Therapy, 2007